Sprung-Navigation
Sharman JP, Biondo JML, Boyer M, Fischer K, Hallek M, Jiang D, Kater AP, Porro Lurà M, Wierda WG
A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies
EJHaem. 2022 Apr 5; 3(2):492-506
doi: 10.1002/jha2.427. eCollection 2022 May. PMID: 35846043
Kutsch N, Pallasch C, Decker T, Hebart H, Chow KU, Graeven U, Kisro J, Kroeber A, Tausch E, Fischer K, Fink AM, Wendtner CM, Ritgen M, Stilgenbauer S, Zhang D, Li B, Jürgensmeier JM, Rajakumaraswamy N, Bhargava P, Hallek M, Eichhorst B
Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
Hemasphere. 2022 May 25; 6(6):e729
doi: 10.1097/HS9.0000000000000729. eCollection 2022 Jun. PMID: 35747845
Langerbeins P, Hallek M.
COVID-19 in patients with hematologic malignancy.
Blood. 2022 Jul 21; 140(3):236-252
doi: 10.1182/blood.2021012251. PMID: 35544585
Rusyn L, Reinartz S, Nikiforov A, Mikhael N, Vom Stein A, Kohlhas V, Bloehdorn J, Stilgenbauer S, Lohneis P, Buettner R, Robrecht S, Fischer K, Pallasch C, Hallek M, Nguyen PH, Seeger-Nukpezah T
The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia.
Leukemia. 2022 Jul; 36(7):1794-1805
doi: 10.1038/s41375-022-01586-1. Epub 2022 May 6. PMID: 35523865
Samineni D, Gibiansky L, Wang B, Vadhavkar S, Rajwanshi R, Tandon M, Sinha A, Al-Sawaf O, Fischer K, Hallek M, Salem AH, Li C, Miles D
Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial.
Adv Ther. 2022 Aug; 39(8):3635-3653
doi: 10.1007/s12325-022-02170-w. Epub 2022 Jun 16. PMID: 35708885
von Tresckow J, Cramer P, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, Fürstenau M, Illmer T, Klaproth H, Tausch E, Ritgen M, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, Böttcher S, Eichhorst BF, Hallek M.
Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
Leukemia. 2022 Aug; 36(8):2125-2128
doi: 10.1038/s41375-022-01629-7. Epub 2022 Jun 25. PMID: 35752657
Fürstenau M, Weiss J, Giza A, Franzen F, Robrecht S, Fink AM, Fischer K, Schneider C, Tausch E, Stilgenbauer S, Ritgen M, Schilhabel A, Brüggemann M, Eichhorst B, Hallek M, Cramer P.
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.
Clin Cancer Res. 2022 Oct 3; 28(19):4203-4211
doi: 10.1158/1078-0432.CCR-22-0433. PMID: 35594173 Clinical Trial
Schilhabel A, Walter PJ, Cramer P, von Tresckow J, Kohlscheen S, Szczepanowski M, Laqua A, Fischer K, Eichhorst B, Böttcher S, Schneider C, Tausch E, Brüggemann M, Kneba M, Hallek M, Ritgen M
CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis
Cancers (Basel). 2022 Oct 7; 14(19):4917
doi: 10.3390/cancers14194917. PMID: 36230840
Cramer P, Fürstenau M, Robrecht S, Giza A, Zhang C, Fink AM, Fischer K, Langerbeins P, Al-Sawaf O, Tausch E, Schneider C, Schetelig J, Dreger P, Böttcher S, Kreuzer KA, Schilhabel A, Ritgen M, Brüggemann M, Kneba M, Stilgenbauer S, Eichhorst B, Hallek M
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
Lancet Haematol. 2022 Oct; 9(10):e745-e755
doi: 10.1016/S2352-3026(22)00211-3. Epub 2022 Aug 18 PMID: 35988545 Clinical Trial
Kutsch N, Fink AM, Fischer K
Management of front line chronic lymphocytic leukemia.
Am J Hematol. 2022 Nov; 97 Suppl 2:S3-S10
doi: 10.1002/ajh.26677. PMID: 36125035
Thomalla D, Beckmann L, Grimm C, Oliverio M, Meder L, Herling CD, Nieper P, Feldmann T, Merkel O, Lorsy E, da Palma Guerreiro A, von Jan J, Kisis I, Wasserburger E, Claasen J, Faitschuk-Meyer E, Altmüller J, Nürnberg P, Yang TP, Lienhard M, Herwig R, Kreuzer KA, Pallasch CP, Büttner R, Schäfer SC, Hartley J, Abken H, Peifer M, Kashkar H, Knittel G, Eichhorst B, Ullrich RT, Herling M, Reinhardt HC, Hallek M, Schweiger MR, Frenzel LP
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies
Blood. 2022 Nov 17; 140(20):2113-2126
doi: 10.1182/blood.2021014304. PMID: 35704690
Knisbacher BA, Lin Z, Hahn CK, Nadeu F, Duran-Ferrer M, Stevenson KE, Tausch E, Delgado J, Barbera-Mourelle A, Taylor-Weiner A, Bousquets-Muñoz P, Diaz-Navarro A, Dunford A, Anand S, Kretzmer H, Gutierrez-Abril J, López-Tamargo S, Fernandes SM, Sun C, Sivina M, Rassenti LZ, Schneider C, Li S, Parida L, Meissner A, Aguet F, Burger JA, Wiestner A, Kipps TJ, Brown JR, Hallek M, Stewart C, Neuberg DS, Martín-Subero JI, Puente XS, Stilgenbauer S, Wu CJ, Campo E, Getz G
Molecular map of chronic lymphocytic leukemia and its impact on outcome
Nat Genet. 2022 Nov; 54(11):1664-1674
doi: 10.1038/s41588-022-01140-w. Epub 2022 Aug 4. PMID: 35927489
Hengeveld PJ, van der Klift MY, Kolijn PM, Davi F, Kavelaars FG, de Jonge E, Robrecht S, Assmann JLJC, van der Straten L, Ritgen M, Westerweel PE, Fischer K, Goede V, Hallek M, Levin MD, Langerak AW
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.
Blood. 2023 Feb 2; 141(5):519-528
doi: 10.1182/blood.2022017411. PMID: 36084320
Simon F, Giza A, Robrecht S, Fink AM, Cramer P, von Tresckow J, Fürstenau M, Goede V, Tausch E, Schneider C, Stilgenbauer S, Wendtner CM, Eichhorst B, Fischer K, Hallek M, Al-Sawaf O
Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older.
Leuk Lymphoma. 2022 Dec; 63(14):3299-3306
doi: 10.1080/10428194.2022.2123223. Epub 2022 Sep 18. PMID: 36120898
Stachelscheid J, Jiang Q, Aszyk C, Warner K, Bley N, Müller T, Vydzhak O, Symeonidis K, Crispatzu G, Mayer P, Blakemore SJ, Goehring G, Newrzela S, Hippler S, Robrecht S, Kreuzer KA, Pallasch C, Krüger M, Lechner A, Fischer K, Stilgenbauer S, Beutner D, Hallek M, Auguin D, Hüttelmaier S, Bloehdorn J, Vasyutina E, Herling M
The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL.
Blood. 2023 Mar 23; 141(12):1425-1441
doi: 10.1182/blood.2022015494. PMID: 36179280
Kutsch N, Holmes EE, Robrecht S, Schüler G, Vehling-Kaiser U, Decker T, Müller-Hagen S, Heinisch K, Böttcher S, Ritgen M, Kreuzer KA, Stilgenbauer S, Fink AM, Fischer K, Eichhorst B, Hallek M, Wendtner CM
Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients.
Leuk Lymphoma. 2023 Feb; 64(2):478-482
doi: 10.1080/10428194.2022.2148210. Epub 2022 Nov 24. PMID: 36423347 No abstract available
de Oliveira TD, Vom Stein A, Rebollido-Rios R, Lobastova L, Lettau M, Janssen O, Wagle P, Nguyen PH, Hallek M, Hansen HP
Stromal cells support the survival of human primary chronic lymphocytic leukemia (CLL) cells through Lyn-driven extracellular vesicles.
Front Med (Lausanne). 2023 Jan 13; 9:1059028
doi: 10.3389/fmed.2022.1059028. eCollection 2022. PMID: 36714146
Vom Stein AF, Rebollido-Rios R, Lukas A, Koch M, von Lom A, Reinartz S, Bachurski D, Rose F, Bozek K, Abdallah AT, Kohlhas V, Saggau J, Zölzer R, Zhao Y, Bruns C, Bröckelmann PJ, Lohneis P, Büttner R, Häupl B, Oellerich T, Nguyen PH, Hallek M.
LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1.
Nat Commun. 2023 Mar 10; 14(1):1330
doi: 10.1038/s41467-023-36824-2. PMID: 36899005
Jiang Q, Stachelscheid J, Bloehdorn J, Pacholewska A, Aszyk C, Grotenhuijs F, Müller T, Onder O, Wagle P, Herling CD, Kleppe M, Wang Z, Coombes KR, Robrecht S, Dalvi PS, Plosnita B, Mayer P, Abruzzo LV, Altmüller J, Gathof B, Persigehl T, Fischer K, Jebaraj B, Rienhoff HY, Ecker R, Zhao Y, Bruns CJ, Stilgenbauer S, Elenitoba-Johnson K, Hallek M, Schweiger MR, Odenthal M, Vasyutina E, Herling M
Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia
Blood. 2023 Jul 6; 142(1):44-61
doi: 10.1182/blood.2022017230. PMID: 37023372
Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, Kotak A, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Chyla B, Paulson JN, Pallasch CP, Frenzel LP, Peifer M, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K.
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Nat Commun. 2023 Apr 18; 14(1):2147
doi: 10.1038/s41467-023-37648-w. PMID: 37072421
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M; GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
N Engl J Med. 2023 May 11; 388(19):1739-1754
doi: 10.1056/NEJMoa2213093. PMID: 37163621 Clinical Trial
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M; GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
N Engl J Med. 2023 May 11; 388(19):1739-1754
doi: 10.1056/NEJMoa2213093. PMID: 37163621 Clinical Trial
Fürstenau M, Thus YJ, Robrecht S, Mellink CHM, van der Kevie-Kersemaekers AM, Dubois J, von Tresckow J, Patz M, Gregor M, Thornton P, Staber PB, Tadmor T, Levin MD, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Janssens A, Christiansen I, Nösslinger T, Baumann M, Hebart H, Gaska T, Regelink JC, Dompeling EC, Lindström V, Juliusson G, Widmer A, Goede J, Goldschmidt N, Simon F, De Silva N, Fink AM, Fischer K, Wendtner CM, Ritgen M, Brüggemann M, Tausch E, Spaargaren M, Eldering E, Stilgenbauer S, Niemann CU, Hallek M, Eichhorst B, Kreuzer KA, Kater AP
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations
Blood. 2023 Aug 3; 142(5):446-459
doi: 10.1182/blood.2023019634. PMID: 37172204 Clinical Trial
Hallek M.
First line therapy of CLL.
Hematol Oncol. 2023 Jun; 41 Suppl 1:129-135
doi: 10.1002/hon.3145. PMID: 37294974
Al Sawaf O.
Importance of MRD in the era of targeted therapies in CLL
Acta Haematol. 2023 Oct 30.
doi: 10.1159/000534846. Epub ahead of print. PMID: 37903476
von Tresckow J, Heyl N, Robrecht S, Giza A, Aldaoud A, Schlag R, Klausmann M, Linde H, Stein W, Schwarzer A, Fischer K, Cramer P, Eichhorst B, Hallek M, Fink AM
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group
Ann Hematol. 2023 Nov; 102(11):3083-3090
doi: 10.1007/s00277-023-05314-2. Epub 2023 Jun 26. PMID: 37358640
Huber H, Tausch E, Schneider C, Edenhofer S, von Tresckow J, Robrecht S, Giza A, Zhang C, Fürstenau M, Dreger P, Ritgen M, Illmer T, Illert AL, Dürig J, Böttcher S, Niemann CU, Kneba M, Al-Sawaf O, Kreuzer KA, Fink AM, Fischer K, Döhner H, Hallek M, Eichhorst B, Stilgenbauer S.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood. 2023 Sep 14; 142(11):961-972
doi: 10.1182/blood.2023020013. PMID: 37363867
Fink A.
Long-term efficacy of ibrutinib-venetoclax for first-line treatment in chronic lymphocytic leukaemia
Lancet Oncol. 2023 Dec; 24(12):1294-1295
doi: 10.1016/S1470-2045(23)00485-0. Epub 2023 Nov 6. PMID: 37944540
Al-Sawaf O, Davids MS.
Overcoming Resistance in Chronic Lymphocytic Leukemia - Maybe Less is More?
Clin Cancer Res. 2023 Dec 6
doi: 10.1158/1078-0432.CCR-23-2872. Epub ahead of print. PMID: 38055246.
Al-Sawaf O, Ligtvoet R, Robrecht S, Stumpf J, Fink AM, Tausch E, Schneider C, Boettcher S, Mikusko M, Ritgen M, Schetelig J, von Tresckow J, Vehling-Kaiser U, Gaska T, Wendtner CM, Chapuy B, Fischer K, Kreuzer KA, Stilgenbauer S, Staber P, Niemann C, Hallek M, Eichhorst B.
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
Nat Med. 2023 Dec 9.
doi: . doi: 10.1038/s41591-023-02722-9. Online ahead of print. PMID: 38071379
Neumann MA, Nieper P, Simon F, Shimabukuro-Vornhagen A, Hallek M, Garcia Borrega J.
A diagnostic challenge-First case of chronic lymphatic leukemia-associated necrotizing sweet syndrome.
Eur J Haematol. 2023 Dec 17.
doi: 10.1111/ejh.14153. Online ahead of print. PMID: 38105522
Vom Stein AF, Hallek M, Nguyen PH.
Role of the tumor microenvironment in CLL pathogenesis.
Semin Hematol. 2023 Dec 26:S0037-1963(23)00098-7
doi: 10.1053/j.seminhematol.2023.12.004. Online ahead of print. PMID: 38220499
Stumpf J, Al-Sawaf O.
Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease
Curr Oncol Rep. 2024 Jan 4.
doi: 10.1007/s11912-023-01482-6. Epub ahead of print. PMID: 38175465.
Kutsch N, Pallasch C, Tausch E, Böhme V, Ritgen M, Liersch R, Wacker A, Jacobs G, Trappe RU, Dreger P,
Fischer K, Fink AM, Stilgenbauer S, Zhai S, Li B, Jürgensmeier JM, Rajakumaraswamy N, Bhargava P, Hallek M,
Eichhorst BF.
Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without
Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
Hemasphere. 2022 Mar 8
doi: 10.1097/HS9.0000000000000692. PMID: 35284802
Huber H, Edenhofer S, von Tresckow J, Robrecht S, Zhang C, Tausch E, Schneider C, Bloehdorn J, Fürstenau M,
Dreger P, Ritgen M, Illmer T, Illert AL, Dürig J, Böttcher S, Niemann CU, Kneba M, Fink AM, Fischer K,
Döhner H, Hallek M, Eichhorst B, Stilgenbauer S.
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic
lymphocytic leukemia.
Blood. 2022 Mar 3
doi: 10.1182/blood.2021013208. PMID: 35108374
Kaddu-Mulindwa D, Altmann B, Robrecht S, Ziepert M, Regitz E, Tausch E, Held G, Poeschel V, Lesan V,
Bittenbring JT, Thurner L, Pfreundschuh M, Christofyllakis K, Truemper L, Loeffler M, Schmitz N, Hoth M,
Hallek M, Fischer K, Stilgenbauer S, Bewarder M, Rixecker TM.
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the
RICOVER-60 and CLL8 trials.
Lancet Haematol. 2022 Feb
doi: 10.1016/S2352-3026(21)00369-0. PMID: 35114151
Mellinghoff SC, Robrecht S, Mayer L, Weskamm LM, Dahlke C, Gruell H, Vanshylla K, Schlösser HA, Thelen M,
Fink AM, Fischer K, Klein F, Addo MM, Eichhorst B, Hallek M, Langerbeins P.
SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic
lymphocytic leukemia.
Leukemia. 2022 Feb
doi: 10.1038/s41375-021-01500-1. PMID: 34937858
Al-Sawaf O, Hallek M, Fischer K.
The role of minimal residual disease in chronic lymphocytic leukemia.
Clin Adv Hematol Oncol. 2022 Feb.
PMID: 35120090
Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, Fink AM, Kreuzer KA,
Vehling-Kaiser U, Tausch E, Müller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M,
Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M.
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic
leukemia.
Blood. 2022 Jan 13
doi: 10.1182/blood.2021010845. PMID: 34758069
Al-Sawaf O, Fischer K
TP53 mutations in CLL: does frequency matter?
Blood. 2021 Dec 23
doi: 10.1182/blood.2021012343. PMID: 34940820
Hallek M, Al-Sawaf O.
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
Am J Hematol. 2021 Dec 1
doi: 10.1002/ajh.26367.PMID: 34625994
Fischer K, Al-Sawaf O.
Acalabrutinib monotherapy in patients with Richter transformation.
Lancet Haematol. 2021 Dec
doi: 10.1016/S2352-3026(21)00334-3. Epub 2021 Nov 1.PMID: 34735861
Fürstenau M, Giza A, Stumpf T, Robrecht S, Maurer C, Linde H, Jacobasch L, Dörfel S, Aldaoud A, von Tresckow
J, Koenigsmann M, Gaska T, Kaiser U, Harich HD, Fischer K, Eichhorst B, Hallek M, Fink AM.
Second primary malignancies in treated and untreated patients with chronic lymphocytic
leukemia.
Am J Hematol. 2021 Dec 1
doi: 10.1002/ajh.26363. Epub 2021 Oct 8.PMID: 34591989
Pflug N, Chakupurakal G, Fink A, Robrecht S, Herling M, Cramer P, Holtick U, Theurich S, Schetelig J, Fischer
K,
Ritgen M, Scheid C, Eichhorst B, Dreger P, Hallek M, Bergwelt-Baildon M
Obinutuzumab in Allogeneic Transplantation for CLL and Richter's Transformation in the Age of
Targeted Therapies
Hemasphere 2021 Nov 12
doi: 10.1097/HS9.0000000000000664 PMID: 34881358
Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, Fink AM, Kreuzer KA,
Vehling-Kaiser U, Tausch E, Müller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M,
Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M.
The CLL12 trial: Ibrutinib versus placebo in treatment-naïve, early stage chronic lymphocytic
leukemia.
Blood. 2021 Nov 10
doi: 10.1182/blood.2021010845. Online ahead of print.PMID: 34758069
Kajüter H, Wellmann I, Khil L, Jöckel KH, Zhang C, Fink AM, Hallek M, Stang A.
Survival of patients with chronic lymphocytic leukemia before and after the introduction of
chemoimmunotherapy in Germany.
Blood Cancer J. 2021 Oct 29
doi: 10.1038/s41408-021-00556-7.PMID: 34716290
Al-Sawaf O, Zhang C, Lu T, Liao MZ, Panchal A, Robrecht S, Ching T, Tandon M, Fink AM, Tausch E, Schneider C,
Ritgen M, Böttcher S, Kreuzer KA, Chyla B, Miles D, Wendtner CM, Eichhorst B, Stilgenbauer S, Jiang Y,
Hallek M, Fischer K.
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment
Follow-up From the Randomized CLL14 Study.
J Clin Oncol, 2021 Oct 28
doi: 10.1200/JCO.21.01181; PMID: 34709929
Al-Sawaf O, Gentile B, Devine J, Zhang C, Sail K, Tandon M, Fink AM, Kutsch N, Wendtner CM, Eichhorst B,
Hallek M, Fischer K.
Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated
chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
Am J Hematol. 2021 Sep 1
doi: 10.1002/ajh.26260. Epub 2021 Jun 22.PMID: 34050972
Fürstenau M, Fink AM, Schilhabel A, Weiss J, Robrecht S, Eckert R, de la Serna J, Crespo M, Coscia M, Vitale
C, Böttcher S, Weppner G, Ritgen M, Stilgenbauer S, Tausch E, Fischer K, Hallek M, Eichhorst B, Brüggemann
M, Herling CD.Blood. 2021 Apr 22;137(16):2267-2271. doi: 10.1182/blood.2020008609.PMID: 33512465
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary
endpoint analysis of a multicenter, open-label phase-II trial.
Cramer P, Tresckow JV, Robrecht S, Bahlo J, Fürstenau M, Langerbeins P, Pflug N, Al-Sawaf O, Heinz WJ,
Vehling-Kaiser U, Dürig J, Tausch E, Hensel M, Sasse S, Fink AM, Fischer K, Kreuzer KA, Böttcher S, Ritgen
M, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M.
B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with
lenalidomide.
Haematologica. 2021 Feb 1
blood.2020010484.
doi: 10.3324/haematol.2019.223693.PMID: 32107341
Cramer P, Tausch E, von Tresckow J, Giza A, Robrecht S, Schneider C, Fürstenau M, Langerbeins P, Al-Sawaf O,
Pelzer BW, Fink AM, Fischer K, Wendtner CM, Eichhorst B, Kneba M, Stilgenbauer S, Hallek M
Durable Remissions Following Combined Targeted Therapy in Patients with CLL Harboring TP53 Deletions
and/or Mutations
Blood. 2021 Jun 4 blood.2020010484.
doi: 10.1182/blood.2020010484. Online ahead of print. PMID: 34086865
Al-Sawaf O, Gentile B, Devine J, Zhang C, Sail K, Tandon M, Fink AM, Kutsch N, Wendtner CM, Eichhorst B,
Hallek M, Fischer K
Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated
chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial
Am J Hematol. 2021 May 29 doi:
10.1002/ajh.26260. Online ahead of print. PMID: 34050972
Bloehdorn J, Krzykalla J, Holzmann K, Gerhardinger A, Jebaraj BMC, Bahlo J, Humphrey K,
Tausch E, Robrecht S, Mertens D, Schneider C, Fischer K, Hallek M, Döhner H, Benner A, Stilgenbauer S
Integrative prognostic models predict long-term survival after immunochemotherapy in chronic
lymphocytic leukemia patients
Haematologica. 2021 Mar 18. doi:
10.3324/haematol.2020.251561. Online ahead of print.
Fürstenau M, Fink AM, Schilhabel A, Weiss J, Robrecht S, Eckert R, de la Serna J, Crespo
M, Coscia M, Vitale C, Böttcher S, Weppner G, Ritgen M, Stilgenbauer S, Tausch E, Fischer K, Hallek M,
Eichhorst B, Brüggemann M, Herling CD
B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with
Lenalidomide
Blood. 2020 Dec
23:blood.2020008609. doi: 10.1182/blood.2020008609. Online ahead of print.
Fischer K, Al-Sawaf O, Hallek M
Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during
treatment of chronic lymphocytic leukemia
Hematology Am
Soc Hematol Educ Program. 2020 Dec 4;2020(1):357-362. doi: 10.1182/hematology.2020000120.
Kohlhaas V, Blakemore SJ, Al-Maarri M, Nickel N, Pal M, Roth A, Hoevelmeyer N, Schäfer SC, Knittel G, Lohneis
P, Nikolic M, Wiederstein JL, Franitza M, Georgomonolis T, Reinart N, Herling M, Herling CD, Hartmann E,
Rosenwald A, Klapper W, Buettner R, Moia R, Rossi D, Boldorini R, Gaidano G, Frenzel LP, Reinhardt C,
Brüning JC, Hallek M, Krüger M, Peifer M, Pallasch CP, Wunderlich FT
Active AKT signaling triggers CLL towards Richter's transformation via over-activation of
Notch1
Blood. 2020 Nov
2:blood.2020005734. doi: 10.1182/blood.2020005734. Online ahead of print.
Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, Gregor M, Cymbalista F,
Buske C, Hillmen P, Hallek M, Mey U; ESMO Guidelines Committee
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up
Ann Oncol. 2020
Oct 19:S0923-7534(20)42469-X doi: 10.1016/j.annonc.2020.09.019. Online ahead of print.
Agathangelidis A et al.
Higher-order connections between stereotyped subsets: implications for improved patient
classification in CLL
Blood. 2020 Sep
29:blood.2020007039 doi: 10.1182/blood.2020007039. Online ahead of print.
Krause G, Hassenrück F, Hallek M
Relevant Cytokines in the B Cell Lymphoma Micro-Environment
Cancers (Basel).
2020 Sep 5;12(9):E2525 doi: 10.3390/cancers12092525
Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, Samoylova O, Liberati AM,
Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ,
Tausch E, Schary W, Ritgen M, Wendtner CM, Kreuzer KA, Eichhorst B, Stilgenbauer S, Hallek M, Fischer K
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic
lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3
trial
Lancet Oncol.
2020 Sep;21(9):1188-1200 doi: 10.1016/S1470-2045(20)30443-5.
Cramer P, von Tresckow J, Eichhorst B, Hallek M
Aktuelle Standards in der Diagnostik und Therapie der chronischen lymphatischen
Leukämie
Dtsch Med
Wochenschr. 2020 Aug;145(16):1139-1144 doi: 10.1055/a-1039-8472. Epub 2020 Aug 13
Barthel R, Fedorchenko O, Velmans T, Rosen N, Nguyen PH, Reinart N, Florin A, Herling M,
Hallek M, Fingerle-Rowson G
CD74 is dispensable for development of chronic lymphocytic leukemia in Eµ-TCL1 transgenic
mice
Leuk Lymphoma.
2020 Jul 15:1-12. doi: 10.1080/10428194.2020.1791851. Online ahead of print.
Fürstenau M, Langerbeins P, De Silva N, Fink AM, Robrecht S, von Tresckow J, Simon F,
Hohloch K, Droogendijk J, van der Klift M, van der Spek E, Illmer T, Schöttker B, Fischer K, Wendtner CM,
Tausch E, Stilgenbauer S, Niemann CU, Gregor M, Kater AP, Hallek M, Eichhorst B
COVID-19 among fit patients with CLL treated with venetoclax-based combinations
Leukemia. 2020
Aug;34(8):2225-2229 doi: 10.1038/s41375-020-0941-7. Epub 2020 Jun 29
Langerbeins P, Fürstenau M, Gruell H, Klein F, Persigehl T, Rybniker J, Seeger-Nukpezah
T, Kochanek M, Hallek M, Eichhorst B, Koehler P, Böll B
COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic
leukemia
Eur J Haematol
2020 Jun 23. doi: 10.1111/ejh.13475. Online ahead of print
Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, Delgado J, Rabe KG,
Gentile M, Doubek M, Mauro FR, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Ekström
Smedby K, Spina V, Bruscaggin A, Wu W, Moia R, Bianchi E, Gerber B, Zucca E, Gillessen S, Ghielmini ME,
Cavalli F, Stuessi G, Hess MA, Baumann TS, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foa R, Pospisilova
S, Morabito F, Stilgenbauer S, Döhner H, Parikh SA, Wierda WG, Montserrat E, Gaidano G, Hallek M, Rossi
D
International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic
Leukemia
Blood. 2020
May 21;135(21):1859-1869 doi: 10.1182/blood.2019003453
Awan FT, Al-Sawaf O, Fischer K, Woyach JA
Current Perspectives on Therapy for Chronic Lymphocytic Leukemia
Am Soc Clin
Oncol Educ Book. 2020 Mar;40:1-10. doi: 10.1200/EDBK_279099
Tausch E, Schneider C, Robrecht S, Zhang C, Dolnik A, Bloehdorn J, Bahlo J, Al-Sawaf O, Ritgen M, Fink AM,
Eichhorst B, Kreuzer KA, Tandon M, Humphrey K, Jiang Y, Schary W, Bullinger L, Mertens D, Porro Lurà M,
Kneba M, Döhner H, Fischer K, Hallek M, Stilgenbauer S
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab
and venetoclax
Blood. 2020
Mar 23. pii: blood.2019004492. doi: 10.1182/blood.2019004492. [Epub ahead of print]
Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, V Tresckow J, Lange E, Kiehl M, Dreyling M, Ritgen M,
Dürig J, Tausch E, Schneider C, Stilgenbauer S, Wendtner CM, Fischer K, Goede 5th, Hallek M, Eichhorst
B
Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study
Group (GCLLSG) front line treatment trials
Leukemia.
2020 Mar 17. doi: 10.1038/s41375-020-0797-x. [Epub ahead of print]
Cramer P, V Tresckow J, Robrecht S, Bahlo J, Fürstenau M, Langerbeins P, Pflug N,
Al-Sawaf O, Heinz WJ, Vehling-Kaiser U, Dürig J, Tausch E, Hensel M, Sasse S, Fink AM, Fischer K, Kreuzer
KA, Böttcher S, Ritgen M, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO):
primary endpoint analysis of a multicentre, open-label phase-II trial
Haematologica.
2020 Feb 27. pii: haematol.2019.223693. doi: 10.3324/haematol.2019.223693. [Epub ahead of print]
Kutsch N, Bahlo J, Robrecht S, Franklin J, Zhang C, Maurer C, De Silva N, Lange E, Weide R, Kiehl MG, Sökler
M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Herling M, Fischer K, Döhner H,
Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Böttcher S, Stilgenbauer S, Fink AM, Hallek M, Eichhorst B
Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients
Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)
Hemasphere.
2020 Jan 27;4(1):e336. doi: 10.1097/HS9.0000000000000336. eCollection 2020 Feb.
Herling CD, Cymbalista F, Groß-Ophoff-Müller C, Bahlo J, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O,
Busch R, Porcher R, Cazin B, Dreyfus B, Ibach S, Leprêtre S, Fischer K, Kaiser F, Eichhorst B, Wentner CM,
Hoechstetter MA, Döhner H, Leblond V, Kneba M, Letestu R, Böttcher S, Stilgenbauer S, Hallek M, Levy V
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic
lymphocytic leukemia (CLL): a randomized phase 3 trial
Leukemia.
2020 Aug;34(8):2038-2050 doi: 10.1038/s41375-020-0747-7. Epub 2020 Feb 18
Al-Sawaf O, Eichhorst B, Hallek M
Chronische lymphatische Leukämie
Internist
(Berl). 2020 Feb 11. doi: 10.1007/s00108-019-00733-8. [Epub ahead of print]
Hoechstetter MA, Busch R, Eichhorst B, Bühler A, Winkler D, Bahlo J, Robrecht S, Eckart MJ, Vehling-Kaiser U,
Jacobs G, Jäger U, Hurtz HJ, Hopfinger G, Hartmann F, Fuss H, Abenhardt W, Blau I, Freier W, Müller L,
Goebeler M, Wendtner C, Fischer K, Herling CD, Starck M, Bentz M, Emmerich B, Döhner H, Stilgenbauer S,
Hallek M
Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter,
prospective CLL1 trial of the German CLL study group
Leukemia.
2020 Apr;34(4):1038-1051 doi: 10.1038/s41375-020-0727-y. Epub 2020 Feb 10
Al-Sawaf O, Lilienweiss E, Bahlo J, Robrecht S, Fink AM, Patz M, Tandon M, Jiang Y, Schary W, Ritgen M,
Tausch E, Stilgenbauer S, Eichhorst B, Fischer K, Hallek M, Kreuzer KA
High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic
lymphocytic leukemia
Blood. 2020
Mar 12;135(11):866-870 doi: 10.1182/blood.2019003451
Agius R, Brieghel C, Andersen MA, Pearson AT, Ledergerber B, Cozzi-Lepri A, Louzoun Y, Andersen CL, Bergstedt
J, von Stemann JH, Jørgensen M, Tang ME, Fontes M, Bahlo J, Herling CD, Hallek M, Lundgren J, MacPherson CR,
Larsen J, Niemann CU
Machine learning can identify newly diagnosed patients with CLL at high risk of
infection
Nat Commun.
2020 Jan 17;11(1):363 doi: 10.1038/s41467-019-14225-8
Jaramillo S, Agathangelidis A, Schneider C, Bahlo J, Robrecht S, Tausch E, Bloehdorn J,
Hoechstetter M, Fischer K, Eichhorst B, Goede V, Hallek M, Döhner H, Rosenquist R, Ghia P, Stamatopoulos K,
Stilgenbauer S
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within
prospective clinical trials of the German CLL Study Group (GCLLSG)
Haematologica.
2019 Dec 26. pii: haematol.2019.231027. doi: 10.3324/haematol.2019.231027. [Epub ahead of print]
Eichhorst B, Fürstenau M, Hallek M
Relapsed disease and aspects of undetectable MRD and treatment discontinuation
Hematology Am
Soc Hematol Educ Program. 2019 Dec 6;2019(1):482-489. doi: 10.1182/hematology.2019000070
Herling CD, Coombes KR, Benner A, Bloehdorn J, Barron LL, Abrams ZB, Majewski T, Bondaruk
JE, Bahlo J, Fischer K, Hallek M, Stilgenbauer S, Czerniak BA, Oakes CC, Ferrajoli A, Keating MJ, Abruzzo LV
Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy
for chronic lymphocytic leukaemia: a retrospective, multicohort study
Lancet Oncol. 2019 Nov;20(11):1576-1586doi:
10.1016/S1470-2045(19)30503-0. Epub 2019 Sep 30
Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, Byrd JC, O'Brien SM,
Dilhuydy MS, Hillmen P, Jaeger U, Moreno C, Cramer P, Stilgenbauer S, Chanan-Khan AA, Mahler M, Salman M,
Eckert K, Solman IG, Balasubramanian S, Cheng M, Londhe A, Ninomoto J, Howes A, James DF, Hallek M
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic
Lymphocytic Leukemia
Clin Lymphoma Myeloma Leuk. 2019
Nov;19(11):715-722.e6 doi: 10.1016/j.clml.2019.07.004. Epub 2019 Jul 15
Fürstenau M, Hopfinger G, Robrecht S, Fink AM, Al-Sawaf O, Langerbeins P, Cramer P,
Tresckow JV, Maurer C, Kutsch N, Hoechstetter M, Dreyling M, Lange E, Kneba M, Stilgenbauer S, Döhner H,
Hensel M, Kiehl MG, Jaeger U, Wendtner CM, Goede V, Fischer K, Bergwelt MV, Eichhorst B, Hallek M, Theurich
S
Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia
(CLL) undergoing rituximab-based chemoimmunotherapy
Leukemia.
2020 Apr;34(4):1177-1181 doi: 10.1038/s41375-019-0630-6. Epub 2019 Nov 14.
Hallek M
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and
treatment
Am J Hematol. 2019 Nov;94(11):1266-128. doi:
10.1002/ajh.25595. Epub 2019 Oct 4
Fürstenau M, Hallek M, Eichhorst B
Sequential and combination treatments with novel agents in chronic lymphocytic
leukemia
Haematologica. 2019 Nov;104(11):2144-2154doi:
10.3324/haematol.2018.208603
Fürstenau M, Bahlo J, Fink AM, Lange E, Dreger P, Dreyling M, Hess G, Ritgen M, Kneba M,
Döhner H, Stilgenbauer S, Wendtner CM, Goede V, Fischer K, Böttcher S, Hallek M, Eichhorst B
Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with
inferior outcome independently of minimal residual disease status in chronic lymphocytic
leukemia
Leukemia.
2020 Mar;34(3):924-928 doi: 10.1038/s41375-019-0597-3. Epub 2019 Oct 14.
Jebaraj BMC, Tausch E, Landau DA, Bahlo J, Robrecht S, Taylor-Weiner AN, Bloehdorn J,
Scheffold A, Mertens D, Böttcher S, Kneba M, Jäger U, Zenz T, Wenger MK, Fingerle-Rowson G, Wendtner C, Fink
AM, Wu CJ, Eichhorst B, Fischer K, Hallek M, Döhner H, Stilgenbauer S
Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in
chronic lymphocytic leukemia
Leukemia. 2019 Sep;33(9):2183-2194 doi: 10.1038/s41375-019-0446-4.
Epub 2019 Mar 25
Edelmann J, Holzmann K, Tausch E, Saunderson EA, Jebaraj BMC, Steinbrecher D, Dolnik A, Blätte TJ, Landau DA,
Saub J, Estenfelder S, Ibach S, Cymbalista F, Leblond V, Delmer A, Bahlo J, Robrecht S, Fischer K, Goede V,
Bullinger L, Wu CJ, Mertens D, Ficz G, Gribben JG, Hallek M, Döhner H, Stilgenbauer S
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key
regulators and NOTCH1 regulated transcription
Haematologica.
2019 Aug 29. pii: haematol.2019.217307. doi: 10.3324/haematol.2019.217307. [Epub ahead of print]
Fürstenau M, De Silva N, Eichhorst B, Hallek M
Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?
Hemasphere. 2019 Aug 9;3(5):e287 doi: 10.1097/HS9.0000000000000287
Kreuzer KA, Furman RR, Stilgenbauer S, Dubowy RL, Kim Y, Munugalavadla V, Lilienweiss E,
Reinhardt HC, Cramer P, Eichhorst B, Hillmen P, O'Brien SM, Pettitt AR, Hallek M
The impact of complex karyotype on the overall survival of patients with relapsed chronic
lymphocytic leukemia treated with idelalisib plus rituximab
Leukemia.
2020 Jan;34(1):296-300 doi: 10.1038/s41375-019-0533-6. Epub 2019 Aug 19.
Fink AM
Is chemoimmunotherapy maintenance of value in patients with chronic lymphocytic leukaemia and
minimal residual disease? (Comment)
Lancet Haematol.
2019 Sep;6(9):e441-e442 doi: 10.1016/S2352-3026(19)30107-3. Epub 2019 Jul 16
Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, Liu CL, Newman AM, Dührsen U, Hüttmann A, Casasnovas O,
Westin JR, Ritgen M, Böttcher S, Langerak AW, Roschewski M, Wilson WH, Gaidano G, Rossi D, Bahlo J, Hallek
M, Tibshirani R, Diehn M, Alizadeh AA
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome
Prediction
Cell. 2019
Jul 25;178(3):699-713.e19 doi: 10.1016/j.cell.2019.06.011. Epub 2019 Jul 4.
Al-Sawaf O, Bazeos A, Robrecht S, Bahlo J, Gower C, Fink AM, Tresckow JV, Cramer P,
Langerbeins P, Kutsch N, Humphrey K, Fingerle-Rowson G, Stilgenbauer S, Wendtner CM, Fischer K, Eichhorst B,
Hallek M, Goede V
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic
leukemia (CLL)
Am J Hematol.
2019 Sep;94(9):1002-1006 doi: 10.1002/ajh.25561. Epub 2019 Jul 8.
Hallek M, Fürstenau M
How to approach CLL in clinical practice
Hematol
Oncol. 2019 Jun;37 Suppl 1:38-42
Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O,
Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S,
Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen
M, Goede V, Stilgenbauer S, Mobasher M, Hallek M
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
N Engl J Med.
2019 Jun 6;380(23):2225-2236
Soumerai JD, Ni A, Xing G, Huang J, Furman RR, Jones J, Sharman JP, Hallek M, Adewoye AH, Dubowy R, Dreiling
L, Zelenetz AD
Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib
phase-3 trials
Leuk Lymphoma. 2019 Jun;60(6):1438-1446 doi:
10.1080/10428194.2018.1540782. Epub 2018 Nov 8
Sachanas S, Pangalis GA, Fink AM, Bahlo J, Fischer K, Levidou G, Kyrtsonis MC, Bartzi V,
Vassilakopoulos TP, Kalpadakis C, Koulieris E, Moschogiannis M, Yiakoumis X, Tsirkinidis P, Angelopoulou MK,
Eichhorst B, Hallek M
Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the
German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical
Trials
Anticancer
Res. 2019 May;39(5):2591-2598
von Tresckow J, Cramer P, Bahlo J, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, Illmer T, Klaproth H,
Estenfelder S, Ritgen M, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, Böttcher S, Eichhorst BF,
Hallek M
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic
lymphocytic leukemia
Leukemia.
2019 May;33(5):1161-1172 doi: 10.1038/s41375-018-0313-8
Pflug N, Cramer P, Robrecht S, Bahlo J, Westermann A, Fink AM, Schrader A, Mayer P, Oberbeck S, Seiler T, Zenz T, Dürig J, Kreuzer KA, Stilgenbauer S, Eichhorst B, Hallek M, Herling M, Hopfinger G
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance
Leuk Lymphoma. 2019 Mar;60(3):649-657 doi: 10.1080/10428194.2018.1488253. Epub 2018 Sep 20
Schetelig J, Link CS, Stuhler G, Wagner EM, Hänel M, Kobbe G, Böttcher S, Kreuzer KA, Middeke JM, Sockel K, Teipel R, von Bonin M, Stölzel F, Kramer M, Stilgenbauer S, Hallek M, Bornhäuser M; Deutsche CLL Studiengruppe and the German Cooperative Transplant Study Group
Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial
Br J Haematol. 2019 Mar;184(5):833-836 doi: 10.1111/bjh.15181. Epub 2018 Mar 12
Tresckow JV, Eichhorst B, Bahlo J, Hallek M
The Treatment of Chronic Lymphatic Leukemia
Dtsch Arztebl
Int. 2019 Jan 25;116(4):41-46
Langerak AW, Ritgen M, Goede V, Robrecht S, Bahlo J, Fischer K, Steurer M, Trněný M, Mulligan SP, Mey UJM,
Trunzer K, Fingerle-Rowson G, Humphrey K, Stilgenbauer S, Böttcher S, Brüggemann M, Hallek M, Kneba M, van
Dongen JJM
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab
or rituximab
Blood. 2019 Jan 31;133(5):494-497 doi: 10.1182/blood-2018-03-839688.
Epub 2018 Nov 19
Eichhorst B, Hallek M, Goede V
Management of unfit elderly patients with chronic lymphocytic leukemia
Eur J Intern
Med. 2018 Dec;58:7-13. doi: 10.1016/j.ejim.2018.02.001. Review
Al-Sawaf O, Bahlo J, Robrecht S, Fischer K, Herling CD, Hoechstetter M, Fink AM, von Tresckow J, Langerbeins
P, Cramer P, Stilgenbauer S, Wendtner CM, Eichhorst B, Hallek M, Goede V
Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia
Br J Haematol. 2018 Dec;183(5):727-735 doi:
10.1111/bjh.15604. Epub 2018 Nov 21
Hallek M
On the architecture of translational research designed to control chronic lymphocytic
leukemia
Hematology Am
Soc Hematol Educ Program. 2018 Nov 30;2018(1):1-8
von Tresckow J, Hallek M, Eichhorst B
Individualisierte Therapie der chronischen lymphatischen
Leukämie
Dtsch Med
Wochenschr. 2018 Sep;143(18):1318-1324 doi: 10.1055/a-0550-2286. Epub 2018 Sep 10
Cramer P, von Tresckow J, Bahlo J, Robrecht S, Langerbeins P, Al-Sawaf O, Engelke A, Fink AM, Fischer K,
Tausch E, Seiler T, Fischer von Weikersthal L, Hebart H, Kreuzer KA, Böttcher S, Ritgen M, Kneba M, Wendtner
CM, Stilgenbauer S, Eichhorst B, Hallek M
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG):
primary endpoint analysis of a multicentre, open-label, phase 2 trial
Lancet Oncol. 2018 Sep;19(9):1215-1228 doi:
10.1016/S1470-2045(18)30414-5. Epub 2018 Aug 13
Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W,
Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S,
Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full
Population of a Phase II Pivotal Trial
J Clin Oncol.
2018 Jul 1;36(19):1973-1980 doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P,
Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T,
Seymour JF, Kipps TJ
iwCLL guidelines for diagnosis, indications for treatment, response assessment and supportive
management of chronic lymphocytic leukemia
Blood. 2018 Jun 21;131(25):2745-2760 doi: 10.1182/blood-2017-09-806398.
Epub 2018 Mar 14
Hallek M, Shanafelt TD, Eichhorst B
Chronic lymphocytic leukaemia
Lancet. 2018 Apr 14;391(10129):1524-1537 Epub 2018
Feb 21.
Dimier N, Delmar P, Ward C, Morariu-Zamfir R, Fingerle-Rowson G, Bahlo J, Fischer K,
Eichhorst B, Goede V, van Dongen JJM, Ritgen M, Böttcher S, Langerak AW, Kneba M, Hallek M
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate
endpoint in CLL
Blood. 2018
Mar 1;131(9):955-962 Epub 2017 Dec 18.
Cramer P, Tresckow JV, Bahlo J, Engelke A, Langerbeins P, Fink AM, Fischer K, Wendtner CM, Kreuzer KA,
Stilgenbauer S, Böttcher S, Eichhorst B, Hallek M
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease
in chronic lymphocytic leukemia
Future Oncol. 2018 Mar;14(6):499-513 doi:
10.2217/fon-2017-0442. Epub 2018 Feb 21.
van Gorkom G, van Gelder M, Eikema DJ, Blok HJ, van Lint MT, Koc Y, Ciceri F, Beelen D,
Chevallier P, Selleslag D, Blaise D, Foá R, Corradini P, Castagna L, Moreno C, Solano C, Müller LP, Tischer
J, Hilgendorf I, Hallek M, Bittenbring J, Theobald M, Schetelig J, Kröger N; CLL subcommittee; Chronic
Malignancies Working Party of the EBMT
Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a
retrospective study on behalf of the chronic malignancies working party of the EBMT
Bone Marrow Transplant. 2018 Mar;53(3):255-263
doi: 10.1038/s41409-017-0023-2. Epub 2017 Dec 18.
Goede V, Hallek M
Welche hämato-onkologischen Medikamente sind im Alter entbehrlich oder ungeeignet?
Dtsch Med
Wochenschr. 2018 Feb;143(4):244-252 doi: 10.1055/s-0043-106791. Epub 2018 Feb 22.
Herling CD, Abedpour N, Weiss J, Schmitt A, Jachimowicz RD, Merkel O, Cartolano M,
Oberbeck S, Mayer P, Berg V, Thomalla D, Kutsch N, Stiefelhagen M, Cramer P, Wendtner CM, Persigehl T, Saleh
A, Altmüller J, Nürnberg P, Pallasch C, Achter V, Lang U, Eichhorst B, Castiglione R, Schäfer SC, Büttner R,
Kreuzer KA, Reinhardt HC, Hallek M, Frenzel LP, Peifer M
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic
leukemia
Nat Commun.
2018 Feb 20;9(1):727
Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, Vasyutina E, Warner K,
Weit N, Pflug N, Braun T, Andersson EI, Yadav B, Riabinska A, Maurer B, Ventura Ferreira MS, Beier F,
Altmüller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brümmendorf TH,
Nürnberg P, Elenitoba-Johnson KSJ, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern MH, Mustjoki S, Newrzela
S, Frommolt P, Herling M
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of
T-PLL
Nat Commun.
2018 Feb 15;9(1):697
Klymenko T, Bloehdorn J, Bahlo J, Robrecht S, Akylzhanova G, Cox K, Estenfelder S, Wang
J, Edelmann J, Strefford JC, Wojdacz TK, Fischer K, Hallek M, Stilgenbauer S, Cragg M, Gribben J, Braun
A
Lamin B1 regulates somatic mutations and progression of B-cell malignancies
Leukemia. 2018 Feb;32(2):364-375
Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N,
Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin
GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S,
Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E
Reproducible diagnosis of Chronic Lymphocytic Leukemia by flow cytometry: an European Research
Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) harmonisation
project
Cytometry B Clin Cytom. 2018
Jan;94(1):121-128
Wolf C, Garding A, Filarsky K, Bahlo J, Robrecht S, Becker N, Zucknick M, Rouhi A, Weigel
A, Claus R, Weichenhan D, Eichhorst B, Fischer K, Hallek M, Kuchenbauer F, Plass C, Döhner H, Stilgenbauer
S, Lichter P, Mertens D
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical
staging and can be inhibited by ibrutinib
Int J Cancer. 2018 Jan 15;142(2):322-333 doi:
10.1002/ijc.31057
Hahn M, Bürckert JP, Luttenberger CA, Klebow S, Hess M, Al-Maarri M, Vogt M, Reißig S,
Hallek M, Wienecke-Baldacchino A, Buch T, Muller CP, Pallasch CP, Wunderlich FT, Waisman A, Hövelmeyer
N
Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic
leukemia via sustained NF-κB signaling
Leukemia.
2018 Jan;32(1):72-82 doi: 10.1038/leu.2017.168
Fischer K, Hallek M
Optimizing frontline therapy of CLL based on clinical and biological factors
Hematology Am
Soc Hematol Educ Program. 2017 Dec 8;2017(1):338-345
Hoechstetter MA, Busch R, Eichhorst B, Bühler A, Winkler D, Eckart MJ, Vehling-Kaiser U, Schimke H, Jäger U,
Hurtz HJ, Hopfinger G, Hartmann F, Fuss H, Abenhardt W, Blau I, Freier W, Müller L, Goebeler M, Wendtner C,
Bahlo J, Fischer K, Bentz M, Emmerich B, Döhner H, Hallek M, Stilgenbauer S
Early, risk-adapted treatment with fludarabine in binet stage a chronic lymphocytic leukemia
patients: Results of the CLL1 trial of the German CLL study group
Leukemia. 2017 Dec;31(12):2833-2837
Tiao G, Improgo MR, Tausch E, Fernandes SM, Bahlo J, Robrecht S, Fischer K, Hallek M, Stilgenbauer S, Kiezun A, Getz G, Brown JR
Analysis of ITGB2 rare germline variants in chronic lymphocytic leukemia
Blood. 2017 Nov 30;130(22):2443-2444
Steinbrecher D, Jebaraj BMC, Schneider C, Edelmann J, Cymbalista F, Leblond V, Delmer A, Ibach S, Tausch E,
Scheffold A, Bloehdorn J, Hallek M, Dreger P, Döhner H, Stilgenbauer S
Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics
and outcome
Leuk
Lymphoma. 2017 Oct 24:1. doi: 10.1080/10428194.2017.1390236. [Epub ahead of print]
Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, von Tresckow J, Maurer C, Bergmann M, Seiler T, Lange E, Kneba M, Stilgenbauer S, Döhner H, Kiehl MG, Jäger U, Wendtner CM, Fischer K, Goede V, Hallek M, Eichhorst B, Hopfinger G
Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukaemia: A meta-analysis by the german CLL study group (GCLLSG)
Leukemia. 2017 Oct;31(10):2251-2253
Scheffold A, Jebaraj BM, Jaramillo S, Tausch E, Steinbrecher D, Hahn M, Böttcher S,
Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner
H, Dreger P, Stilgenbauer S
Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk
chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial
Br J Haematol. 2017 Oct;179(2):342-346
Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel
S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E,
Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia
(CLLM1): final results from a randomised, double-blind, phase 3 study
Lancet Haematol. 2017 Oct;4(10):e475-e486 doi:
10.1016/S2352-3026(17)30171-0
Krämer I, Stilgenbauer S, Dietrich S, Böttcher S, Zeis M, Stadler M, Bittenbring J, Uharek L, Scheid C, Hegenbart U, Ho A, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial
Blood. 2017 Sep 21;130(12):1477-1480
Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ,
Shanafelt TD, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfò L,
Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan Djurasevic T, Catherwood MA, Kienle D, Chatzouli M,
Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis
P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antic D, Trentin L, Montillo M, Niemann CU, Dohner H,
Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF,
Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P,
Stamatopoulos K
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic
Features and Clinical Outcomes
Clin Cancer Res.
2017 Sep 1;23(17):5292-5301
Hallek M
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and
treatment
Am J Hematol.
2017 Sep;92(9):946-965
Knittel G, Rehkämper T, Korovkina D, Liedgens P, Fritz C, Torgovnick A, Al-Baldawi Y,
Al-Maarri M, Cun Y, Fedorchenko O, Riabinska A, Beleggia F, Nguyen PH, Wunderlich FT, Ortmann M,
Montesinos-Rongen M, Tausch E, Stilgenbauer S, P Frenzel L, Herling M, Herling C, Bahlo J, Hallek M, Peifer
M, Buettner R, Persigehl T, Reinhardt HC
Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic
leukemia
Nat Commun.
2017 Jul 28;8(1):153
Tiao G, Improgo MR, Kasar S, Poh W, Kamburov A, Landau DA, Tausch E, Taylor-Weiner A,
Cibulskis C, Bahl S, Fernandes SM, Hoang K, Rheinbay E, Kim HT, Bahlo J, Robrecht S, Fischer K, Hallek M,
Gabriel S, Lander ES, Stilgenbauer S, Wu CJ, Kiezun A, Getz G, Brown JR
Rare germline variants in ATM are associated with chronic lymphocytic leukemia
Leukemia.
2017 Jun 27 [Epub ahead of print]
Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J, Call TG, Schwager
SM, Ding W, Eichhorst B, Fischer K, Leis JF, Chanan-Khan AA, Hallek M, Slager SL, Kay NE
Arial fibrillation in patients with chronic lymphocytic leukemia (CLL)
Leuk Lymphoma. 2017 Jul;58(7):1630-1639
Hallek M
Role and timing of new drugs in CLL
Hematol
Oncol. 2017 Jun;35 Suppl 1:30-32
Göckeritz E, Vondey V, Guastafierro A, Pizevska M, Hassenrück F, Neumann L, Hallek M, Krause G
Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells
and cell functions involved in the micro-environmental dialogue
Br J Haematol. 2017 Sep;178(6):949-953 doi:
10.1111/bjh.14781. Epub 2017 Jun 1
Al-Sawaf O, Cramer P, Goede V, Hallek M, Pflug N
Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a
perspective review
Ther Adv
Hematol. 2017 Jun;8(6):197-205
Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps TJ, Weinkove R, Robinson S, Seiler T,
Opat S, Owen C, López J, Humphrey K, Humerickhouse R, Tausch E, Frenzel L, Eichhorst B, Wendtner CM,
Stilgenbauer S, Langerak AW, van Dongen JJ, Boettcher S, Ritgen M, Goede V, Mobasher M, Hallek M
Venetoclax and obinutuzumab in chronic lymphocytic leukemia
Blood. 2017
May 11;129(19):2702-2705
Lohmann G, Vasyutina E, Bloehdorn J, Reinart N, Schneider JI, Babu V, Knittel G, Crispatzu G, Mayer P, Prinz
C, Muenzner JK, Biersack B, Efremov DG, Chessa L, Herling CD, Stilgenbauer S, Hallek M, Schobert R,
Reinhardt HC, Schumacher B, Herling M
Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic
lymphocytic leukemia
Leukemia. 2017 May;31(5):1177-1186
Jerkeman M, Hallek M, Dreyling M, Thieblemont C, Kimby E, Staudt L
Targeting of B-cell receptor signalling in B-cell malignancies
J Intern Med.
2017 Mar 14 doi: 10.1111/joim.12600. [Epub ahead of print]
Al-Sawaf O, Fischer K, Herling CD, Ritgen M, Böttcher S, Bahlo J, Elter T, Stilgenbauer
S, Eichhorst BF, Busch R, Elberskirch U, Abenhardt W, Kneba M, Hallek M, Wendtner CM
Alemtuzumab consolidation in chronic lymphocytic leukaemia: A phase I/II multicentre
trial
Eur J
Haematol. 2017 Mar;98(3):254-262
Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer K, Fink AM, Bloehdorn J,
Holzmann K, Böttcher S, Werner L, Kneba M, Gribben JG, Neuberg DS, Wu CJ, Hallek M, Döhner H, Stilgenbauer S
Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is
enriched with TP53 alterations: results from the CLL8 trial
Leukemia. 2017 Mar;31(3):734-738
Reiners KS, Shatnyeva O, Vasyutina E, Bösl T, Hansen HP, Hallek M, Herling M, Pogge von
Strandmann E Elke Pogge
Extracellular vesicles released from chronic lymphocytic leukemia cells exhibit a disease relevant
mRNA signature and transfer mRNAs to bystander cells
Haematologica. 2017 Mar;102(3):e100-e103
Al-Sawaf O, Fischer K, Engelke A, Pflug N, Hallek M, Goede V
Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
Drug Des
Devel Ther. 2017 Jan 25;11:295-304
Kutsch N, Busch R, Bahlo J, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U,
Wendtner CM, Maria Fink A, Fischer K, Hallek M, Eichhorst B
FCR front-line therapy and quality of life in patients with chronic lymphocytic
leukemia
Leuk Lymphoma. 2017 Feb;58(2):399-407
Eichhorst B, Hallek M
Prognostication of chronic lymphocytic leukemia in the era of new agents
Hematology Am
Soc Hematol Educ Program. 2016 Dec 2;2016(1):149-155
Al-Sawaf O, Fischer K, Eichhorst B, Hallek M
Targeted Therapy of CLL
Oncol Res
Treat. 2016;39(12):768-778
Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, Maurer C, Langerbeins P, Fingerle-Rowson G,
Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Klapper W, Wendtner CM, Fischer K, Hallek M, Eichhorst B,
Böttcher S
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic
Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies
of the German CLL Study Group
J Clin Oncol.
2016 Nov 1;34(31):3758-3765
Nguyen PH, Fedorchenko O, Rosen N, Koch M, Barthel R, Winarski T, Florin A, Wunderlich
FT, Reinart N, Hallek M
LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic
Leukemia
Cancer Cell.
2016 Oct 10;30(4):610-622
Maurer C, Langerbeins P, Bahlo J, Cramer P, Fink AM, Pflug N, Engelke A, von Tresckow J,
Kovacs G, Stilgenbauer S, Wendtner CM, Müller L, Ritgen M, Seiler T, Fischer K, Hallek M, Eichhorst B
Effect of first-line treatment on second primary malignancies and Richter's transformation in
patients with chronic lymphocytic leukemia (CLL)
Leukemia. 2016 Oct;30(10):2019-2025
Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C; ESMO Guidelines
Committee
eUpdate – Chronic Lymphocytic Leukaemia Treatment Recommendations (ESMO)
Ann Oncol.
2016 Sep;27(suppl 5):v143-v144
Eichhorst B, Hallek M, Goede V
New treatment approaches in CLL: Challenges and opportunities in the elderly
J Geriatr Oncol. 2016 Sep;7(5):375-82
Maurer C, Pflug N, Bahlo J, Kluth S, Rhein C, Cramer P, Gross-Ophoff C, Langerbeins P,
Fink AM, Eichhorst B, Kreuzer KA, Fischer N, Tausch E, Stilgenbauer S, Böttcher S, Döhner H, Kneba M,
Dreyling M, Binder M, Hallek M, Wendtner CM, Bergmann M, Fischer K; German CLL Study Group
Bendamustine and Rituximab in Combination with Lenalidomide in Patients with Chronic Lymphocytic
Leukemia
Eur J Haematol. 2016 Sep;97(3):253-60
Louise Freeman C, Dixon M, Houghton R, Kreuzer KA, Fingerle-Rowson G, Herling M, Humphrey K, Böttcher S, de Costa CS, Iglesias V, Stilgenbauer S, Gribben J, Hallek M,
Goede V
Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
Leukemia. 2016 Aug;30(8):1763-6
Vyas M, Schneider AC, Shatnyeva O, Reiners KS, Tawadros S, Kloess S, Köhl U, Hallek M, Hansen HP, Pogge von
Strandmann E
Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in
vitro and in vivo against chronic lymphocytic leukemia
Oncoimmunology.
2016 Jul 15;5(9):e1211220
Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodríguez MS,
Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IA, van Kampen RJ, Hege K, Kersten MJ,
Trowe T, Filvaroff EH, Eldering E, Kater AP
Dual TORK/DNA-PK inhibition blocks critical signalling pathways in chronic lymphocytic
leukemia
Blood. 2016 Jul 28;128(4):574-83
Herling CD, Klaumünzer M, Krings Rocha C, Altmüller J, Thiele H, Bahlo J, Kluth S,
Crispatzu G, Herling M, Schiller J, Engelke A, Tausch E, Döhner H, Fischer K, Goede V, Nürnberg P, Reinhardt
HC, Stilgenbauer S, Hallek M, Kreuzer KA
Complex karyotypes, KRAS and POT1 mutations impact outcome in CLL after chlorambucil based chemo- or
chemoimmunotherapy
Blood. 2016 Jul 21;128(3):395-404
Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M,
Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner
H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; international group of
investigators; German CLL Study Group (GCLLSG)
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide,
and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international,
open-label, randomised, phase 3, non-inferiority trial
Lancet Oncol. 2016 Jul;17(7):928-42
The International CLL-IPI working group
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a
meta-analysis of individual patient data
Lancet Oncol.
2016 Jun;17(6):779-90
CLL-IPI
Online Calculator
Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Lancet Oncol. 2016 Jun;17(6):768-78
Brown JR, Hallek MJ, Pagel JM
Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How
Much, and in Which Combination?
Am Soc Clin
Oncol Educ Book. 2016;35:e387-98
Lilienthal N, Lohmann G, Crispatzu G, Vasyutina E, Zittrich S, Mayer P, Herling CD, Tur
MK, Hallek M,
Pfitzer G, Barth S, Herling M
A Novel Recombinant Anti-CD22 Immunokinase Delivers Proapoptotic Activity of Death-Associated
Protein Kinase (DAPK) and Mediates Cytotoxicity in Neoplastic B Cells
Mol Cancer
Ther. 2016 May;15(5):971-84
Cramer P, Langerbeins P, Fischer K, Eichhorst B, Hallek M, Goede V
Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic
lymphocytic leukemia: does one size fit all?
Leuk Lymphoma.
2016 May;57(5):987-990
Lilienthal N, Lohmann G, Crispatzu G, Vasyutina E, Zittrich S, Mayer P, Herling CD, Tur MK, Hallek M, Pfitzer G, Barth S, Herling M
A novel recombinant anti-CD22 immunokinase delivers pro-apoptotic activity of death-associated protein kinase (DAPK) and mediates cytotoxicity in neoplastic B-cells
Mol Cancer Ther. 2016 May;15(5):971-84
Müller D, Fischer K, Kaiser P, Eichhorst B, Walshe R, Reiser M, Kellermann L, Borsi L, Civello D, Mensch A,
Bahlo J, Hallek M, Stock S, Fingerle-Rowson G
Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the
first-line treatment of chronic lymphocytic leukemia
Leuk Lymphoma.
2016 May;57(5):1130-9
Pflug N, Kluth S, Vehreschild JJ, Bahlo J, Tacke D, Biehl L, Eichhorst B, Fischer K, Cramer P, Fink AM, von
Bergwelt-Baildon M, Stilgenbauer S, Hallek M, Cornely OA, Vehreschild MJ
Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate
intestinal microbiota
Oncoimmunology.
2016 Apr 22;5(6):e1150399
Eichhorst B, Cramer P, Hallek M
Initial therapy of chronic lymphocytic leukemia
Semin Oncol.
2016 Apr;43(2):241-50
Hellmich S, Schreiber N, Fath B, Hallek M
Fortschritt durch vernetzte Strukturen: Herausforderungen für das Kompetenznetz Maligne Lymphome im
Zeitalter der Präzisionsmedizin
Bundesgesundheitsblatt
Gesundheitsforschung Gesundheitsschutz. 2016 Apr;59(4):454-64
Goede V, Bahlo J, Chataline V, Eichhorst B, Dürig J, Stilgenbauer S, Kolb G, Honecker F,
Wedding U, Hallek M
Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the
CLL9 trial of the German CLL Study Group
Leuk Lymphoma. 2016 Apr;57(4):789-96
Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C,
Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater
AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL,
Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M,
Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A,
Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P
A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal
residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative
on CLL (ERIC) study
Leukemia.
2016 Apr;30(4):929-36
Goede V, Busch R, Bahlo J, Chataline V, Kremers S, Müller L, Reschke D, Schlag R, Schmidt
B, Vehling-Kaiser U, Wedding U, Stilgenbauer S, Hallek M
Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia
and comorbidity: Primary results of the CLL9 trial of the German CLL Study Group
Leuk Lymphoma. 2016 Mar;57(3):596-603
Cramer P, Eichhorst B, Reinhardt HC, Hallek M
Current strategies to create tailored and risk-adapted therapies for CLL patients
Best Pract
Res Clin Haematol. 2016 Mar;29(1):111-121
Bühler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Dürig J, Gregory SA,
Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J,
Hallek M, Stilgenbauer S
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic
leukemia: data from the prospective, multicenter phase-II CLL-009 trial
Blood Cancer
J. 2016 Mar 11;6:e404
Cramer P, Hallek M, Eichhorst B
State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia
Oncol Res
Treat. 2016;39(1-2):25-32
Langerbeins P, Groß-Ophoff-Müller C, Herling CD
Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia
Oncol Res
Treat. 2016;39(1-2):18-24
Frenzel LP, Reinhardt HC, Pallasch CP
Concepts of Chronic Lymphocytic Leukemia Pathogenesis: DNA Damage Response and Tumor
Microenvironment
Oncol Res
Treat. 2016;39(1-2):9-16
Cramer P, Langerbeins P, Hallek M
Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New
Monoclonal Antibodies in Combination With Ibrutinib
Cancer J. 2016
Jan-Feb;22(1):62-66
Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens
A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O,
Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C,
Balasubramanian S, Howes A, Hallek M; HELIOS investigators
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and
rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a
randomised, double-blind, phase 3 study
Lancet Oncol. 2016 Feb;17(2):200-11
Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow
J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer KA, Eichhorst B, Böttcher S, Seymour JF, Ghia
P, Marlton P, Kneba M, Wendtner CM, Döhner H, Stilgenbauer S, Hallek M
Long term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated
results of the CLL8 trial
Blood. 2016 Jan 14;127(2):208-15
Cramer P, Langerbeins P, Eichhorst B, Hallek M
Advances in first-line treatment of chronic lymphocytic leukemia current recommendations on
management and first-line treatment by the German CLL Study Group (GCLLSG)
Eur J Haematol. 2016 Jan;96(1):9-18
Kirsten Fischer, Anna-Maria Fink, Helen Bishop, Mark Dixon, Jasmin Bahlo, Michael Y.
Choi, Robert Weinkove, K. Sue Robinson, Martin Dreyling, Till Seiler, Stephen Opat, Carolyn Owen, Javier
Lopez Sr., Nadine Kutsch, Eugen Tausch, Matthias Ritgen, Rod A. Humerickhouse, Kathryn Humphrey, Michael K.
Wenger, Valentin Goede, Barbara Eichhorst, Clemens-Martin Wendtner, Stephan Stilgenbauer, Thomas J. Kipps
and Michael Hallek
Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter
Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax
(GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and
Coexisting Medical Conditions (ASH Abstract)
Blood 2015
Dec 03;126(23):496
Cramer P, Isfort S, Bahlo J, Stilgenbauer S, Döhner H, Bergmann M, Stauch M, Kneba M,
Lange E, Langerbeins P, Pflug N, Kovacs G, Goede V, Fink AM, Elter T, Fischer K, Wendtner CM, Hallek M,
Eichhorst B
Outcome of advanced chronic lymphocytic leukemia following different firstline- and
relapse-therapies: A metaanalysis of five prospective trials of german CLL study group (GCLLSG)
Haematologica.
2015 Nov;100(11):1451-9
Göckeritz E, Kerwien S, Baumann M, Wigger M, Vondey V, Neumann L, Landwehr T, Wendtner CM, Klein C, Liu N,
Hallek M, Frenzel LP, Krause G
Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for
inhibiting the survival of chronic lymphocytic leukemia cells
Int J Cancer.
2015 Nov 1;137(9):2234-42
Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher
S, Carter SL, Cibulskis K, Mertens D, Sougnez CL, Rosenberg M, Hess JM, Edelmann J, Kless S, Kneba M, Ritgen
M, Fink A, Fischer K, Gabriel S, Lander ES, Nowak MA, Döhner H, Hallek M, Neuberg D, Getz G, Stilgenbauer S,
Wu CJ
Mutations driving CLL and their evolution in progression and relapse
Nature. 2015
Oct 22;526(7574):525-30
Goede V, Hallek M
Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New
Agents, New Hope
Drugs Aging. 2015 Nov;32(11):877-86
Göckeritz E, Kerwien S, Baumann M, Wigger M, Vondey V, Neumann L, Landwehr T, Wendtner
CM, Klein C, Liu N, Hallek M, Frenzel LP, Krause G
Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for
inhibiting the survival of chronic lymphocytic leukemia cells
Int J Cancer.
2015 Nov 1;137(9):2234-42
Chakupurakal G, Leitzke S, Langerbeins P, Schiller J, Schneider PM, Holtick U, Shimabukuro-Vornhagen A,
Theurich S, Chemnitz J, Hallek M, von Bergwelt-Baildon M, Scheid C
Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the
possibility of disease control with minimal morbidity and mortality-a single institution
experience
Ann Hematol.
2015 Oct;94(10):1717-25
Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up
Ann Oncol.
2015 Sep;26 Suppl 5:v78-v84
Langerbeins P, Bahlo J, Rhein C, Cramer P, Pflug N, Fischer K, Stilgenbauer S, Kreuzer KA, Wendtner CM,
Eichhorst B, Hallek M
The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the
treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease
progression
Future Oncol.
2015 Jul;11(13):1895-903
Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LF, Montillo M, Fegan C, Asikanius E, Humphrey K, Fingerle-Rowson G, Hallek M
Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: Updated results of the CLL11 study
Leukemia. 2015 Jul;29(7):1602-4
Schrader A, Popal W, Lilienthal N, Crispatzu G, Mayer P, Jones D, Hallek M, Herling M
AKT-pathway inhibition in chronic lymphocytic leukemia reveals response relationships defined by
TCL1
Curr Cancer
Drug Targets. 2014;14(8):700-12
Vollbrecht C, Mairinger FD, Koitzsch U, Peifer M, Koenig K, Heukamp LC, Crispatzu G, Wilden L, Kreuzer KA,
Hallek M, Odenthal M, Herling CD, Buettner R
Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex
PCR-Based Next Generation Sequencing
PLoS One. 2015
Jun 8;10(6):e0129544
Goede V, Eichhorst B, Fischer K, Wendtner CM, Hallek M
Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia
Leuk Lymphoma. 2015 Jun;56(6):1585-92
Prinz C, Vasyutina E, Lohmann G, Schrader A, Romanski S, Hirschhäuser C, Mayer P, Frias C, Herling CD, Hallek
M, Schmalz HG, Prokop A, Mougiakakos D, Herling M
Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS
dependent and facilitated by TCL1-oncogene burden
Mol Cancer.
2015 Jun 4;14(1):114
Holtick U, Chemnitz JM, Hallek M, Scheid C
Allogene Blutstammzelltransplantation – ein Überblick
Klin Monbl
Augenheilkd. 2015 May;232(5):641-6
Hallek M
Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and
treatment
Am J Hematol.
2015 May;90(5):446-60
Goede V, Hallek M
Towards improved frontline treatment of CLL in the elderly
Lancet. 2015
May 9;385(9980):1814-5
Berg V, Rusch M, Vartak N, Jüngst C, Schauss A, Waldmann H, Hedberg C, Pallasch CP, Bastiaens PI, Hallek M, Wendtner CM, Frenzel LP
miRs-138 and -424 control palmitoylation-dependent CD95-mediated cell death by targeting acyl protein thioesterases 1 and 2 in chronic lymphocytic leukemia
Blood. 2015 May 7;125(19):2948-57
Langerbeins P, Maurer C, Cramer P, Eichhorst B, Hallek M
Second cancers in chronic lymphocytic leukemia: Growing importance in the era of improved treatment
outcomes
Leuk Lymphoma.
2015 May 12:1-2
Hallek M
Klinische Forschung in Deutschland: Bürokratieabbau jetzt wagen!
Dtsch Med
Wochenschr. 2015 Apr;140(7):463-4
Eichhorst B, Hallek M
Erratum zu: Chronische lymphatische Leukämie.Therapiekonzepte im Wandel
Internist
(Berl). 2017 Aug 18 [Epub ahead of print]
Eichhorst B, Hallek M
Chronische lymphatische Leukämie - Therapiekonzepte im Wandel
Internist (Berl). 2015 Apr;56(4):374-80
Kutsch N, Hallek M, Eichhorst B
Emerging therapies for refractory CLL
Leuk Lymphoma. 2015 Feb;56(2):285-92
Stilgenbauer S, Cymbalista F, Leblond V, Delmer A, Ibach S, Choquet S, Dartigeas C, Cazin
B, Tournilhac O, Pegourie B, Seiler TM, Sökler M, Zirlik K, Alt J, Huber H, Bloehdorn J, Tausch E, Zenz T,
Hallek M, Schetelig J, Dreger P, Döhner H
Alemtuzumab combined with dexamethasone, followed by alemtuzumab maintenance or Allo-SCT in “ultra
High-risk” CLL: final results from the CLL2O phase II study
Blood.
2014;124:1991
Langerbeins P, Busch R, Anheier N, Dürig J, Bergmann M, Goebeler ME, Hurtz HJ, Stauch
MB, Stilgenbauer S, Döhner H, Fink AM, Cramer P, Fischer K, Wendtner CM, Hallek M, Eichhorst B
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and
Richter transformation
Am J Hematol.
2014 Dec;89(12):E239-43
Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J, Kimby E,
Michallet M, Moreno C, Stilgenbauer S, Montserrat E; European Research Initiative on CLL (ERIC) and the
European Society for Blood and Marrow Transplantation (EBMT)
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel
agents?
Blood. 2014
Dec 18;124(26):3841-9
Pallasch CP, Hallek M
Incorporating targeted agents into future therapy of chronic lymphocytic leukemia
Semin Hematol.
2014 Jul;51(3):235-48
Weisser M, Yeh RF, Duchateau-Nguyen G, Palermo G, Nguyen TQ, Shi X, Stinson SY, Yu N, Dufour A, Robak T,
Salogub GN, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Larratt L, Rossiev VA,
Bence-Bruckler I, Geisler CH, Montillo M, Fischer K, Fink AM, Hallek M, Bloehdorn J, Busch R, Benner A,
Döhner H, Valente N, Wenger MK, Stilgenbauer S, Dornan D
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia
Blood. 2014
Jul 17;124(3):420-5
Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, Bauer K, Malchau G, Rabe KG, Stilgenbauer
S, Döhner H, Jäger U, Eckart MJ, Hopfinger G, Busch R, Fink AM, Wendtner CM, Fischer K, Kay NE, Hallek
M
Development of a comprehensive prognostic index for patients with chronic lymphocytic
leukemia
Blood. 2014
Jul 3;124(1):49-62
Goede V, Cramer P, Busch R, Bergmann M, Stauch M, Hopfinger G, Stilgenbauer S, Doehner H, Westermann A,
Wendtner CM, Eichhorst B, Hallek M
Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German
Chronic Lymphocytic Leukemia Study Group trials
Haematologica.
2014 Jun;99(6):1095-100
Ghia P, Hallek M
Management of chronic lymphocytic leukemia
Haematologica.
2014 Jun;99(6):965-972
Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, Bühler A, Böttcher S, Ritgen M, Kneba M,
Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, Jäger U,
Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch
R, Hallek M, Döhner H
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8
trial
Blood. 2014
May 22;123(21):3247-54
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS,
Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba
M, Asikanius E, Humphrey K, Wenger M, Hallek M
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
N Engl J Med.
2014 Mar 20;370(12):1101-10
Cramer P, Bahlo J, Eichhorst B, Fischer K, Hallek M
Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual
Leuk Res. 2013
Dec 1. pii: S0145-2126(13)00416-5
Hallek M
Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies
Hematology Am
Soc Hematol Educ Program. 2013;2013:138-50
Blood. 2013 Nov 28;122(23):3723-34
Maurer C, Hallek M
Chronische lymphatische Leukämie
Dtsch Med
Wochenschr. 2013 Oct;138(42):2153-66
Hallek M
Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and
treatment
Am J Hematol.
2013 Sep;88(9):803-16
Fink AM, Böttcher S, Ritgen M, Fischer K, Pflug N, Eichhorst B, Wendtner CM, Winkler D, Bühler A, Zenz T,
Staib P, Mayer J, Hensel M, Hopfinger G, Wenger M, Fingerle-Rowson G, Döhner H, Kneba M, Stilgenbauer S,
Busch R, Hallek M
Prediction of poor outcome in CLL patients following first-line treatment with fludarabine,
cyclophosphamide and rituximab
Leukemia. 2013
Sep;27(9):1949-52
Göbel M, Eisele L, Möllmann M, Hüttmann A, Johansson P, Scholtysik R, Bergmann M, Busch R, Döhner H, Hallek
M, Seiler T, Stilgenbauer S, Klein-Hitpass L, Dührsen U, Dürig J
Progranulin is a novel independent predictor of disease progression and overall survival in chronic
lymphocytic leukemia
PLoS One. 2013
Aug 23;8(8):e72107
Schnaiter A, Paschka P, Rossi M, Zenz T, Bühler A, Winkler D, Cazzola M, Döhner K, Edelmann J, Mertens D,
Kless S, Mack S, Busch R, Hallek M, Döhner H, Stilgenbauer S
NOTCH1, SF3B1 and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab:
results from the CLL2H trial of the GCLLSG
Blood. 2013
Aug 15;122(7):1266-70
Cramer P, Fink AM, Busch R, Eichhorst B, Wendtner C, Pflug N, Langerbeins P, Bahlo J, Goede V, Schubert F,
Döhner H, Stigenbauer S, Dreger P, Kneba M, Böttcher S, Mayer J, Hallek M, Fischer K
Second-line Therapies of Patients initially treated with Fludarabine and Cyclophosphamide (FC) or
Fludarabine, Cyclophosphamide and Rituximab (FCR) for Chronic Lymphocytic Leukemia (CLL) within the
CLL8-Protocol of the German CLL Study Group (GCLLSG)
Leuk Lymphoma.
2013 Aug;54(8):1821-2
Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink AM, Cramer P, Reinart N, Winkler D, Fingerle-Rowson
G, Stilgenbauer S, Döhner H, Kandler G, Eichhorst B, Hallek M, Herling M
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed
by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia
Cancer. 2013
Jun 15;119(12):2258-67
Goede V, Fischer K, Busch R, Jaeger U, Dilhuydy MS, Wickham N, De Guibert S, Ritgen M, Langerak AW, Bieska G,
Engelke A, Humphrey K, Wenger M, Hallek M
Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and
comorbidity: results of the CLL11 (BO21004) safety run-in
Leukemia. 2013
Apr;27(5):1172-4
Dreger P, Schnaiter A, Zenz T, Böttcher S, Rossi M, Paschka P, Bühler A, Dietrich S, Busch R, Ritgen M,
Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H,
Stilgenbauer S
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic
leukemia: six-year follow-up of the GCLLSG CLL3X trial
Blood. 2013
Apr 18;121(16):3284-8
Hallek M, Knauf W, Dreyling M, Trümper L
Aktuelle und künftige Indikationen mit Bendamustin:
chronische lymphatische Leukämie, indolente
Lymphome, Mantelzell-Lymphome und diffuse großzellige
B-Zell-Lymphome
Onkologie.
2013;36 Suppl 1:11-8
Stilgenbauer S, Hallek M
Chronische lymphatische Leukämie: Therapie und genetisches Risikoprofil
Internist
(Berl). 2013 Feb;54(2):164-70
Elter T, James R, Busch R, Winkler D, Ritgen M, Böttcher S, Kahl C, Gassmann W, Stauch M, Hasan I, Staib
P, Fischer K, Fink AM, Bahlo J, Bühler A, Döhner H, Wendtner CM, Stilgenbauer S, Engert A, Hallek
M writtrn on behalf of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG)
Fludarabine and cyclophosphamide in combination with alemtuzumab (FCCam) in patients with primary
high-risk, relapsed or refractory chronic lymphocytic leukemia
Leukemia. 2012
Dec;26(12):2549-52
Edelmann J, Holzmann K, Miller F, Winkler D, Bühler A, Zenz T, Bullinger L, Kühn MW, Gerhardinger A,
Bloehdorn J, Radtke I, Su X, Ma J, Pounds S, Hallek M, Lichter P, Korbel J, Busch R, Mertens D, Downing JR,
Stilgenbauer S, Döhner H
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic
alterations
Blood. 2012
Dec 6;120(24):4783-94
Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, Pflüger KH, Schott S, Goede V, Isfort S, von
Tresckow J, Fink AM, Bühler A, Winkler D, Kreuzer KA, Staib P, Ritgen M, Kneba M, Döhner H, Eichhorst BF,
Hallek M, Stilgenbauer S, Wendtner CM
Bendamustine in combination with rituximab for previously untreated patients with chronic
lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study
Group
J Clin Oncol.
2012 Sep 10;30(26):3209-16
Köppler H, Fuss H, Hurtz HJ, Knigge O, Losem C, Reschke D, Schmitz S, Weide R, Weiß J, Hallek M;
for the GCLLSG
Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results
of a multicentre phase II study of the German CLL Study Group (GCLLSG)
Br J Haematol.
2012 Jul;158(2):238-41
Isfort S, Cramer P, Hallek M
Novel and emerging drugs for chronic lymphocytic leukemia
Curr Cancer
Drug Targets. 2012 Jun;12(5):471-83
Dreger P, Döhner H, McClanahan F, Busch R, Ritgen M, Greinix H, Fink AM, Knauf W, Stadler M,
Pfreundschuh M, Dührsen U, Brittinger G, Hensel M, Schetelig J, Winkler D, Bühler A, Kneba M,
Schmitz N, Hallek M, Stilgenbauer S
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of
the GCLLSG CLL3 trial
Blood. 2012
May 24;119(21):4851-4859
Zenz T, Gribben JG, Hallek M, Döhner H, Keating MJ, Stilgenbauer S.
Risk categories and refractory CLL in the era of chemoimmunotherapy
Blood. 2012 May 3;119(18):4101-7
Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, Fink AM, Bühler A,
Zenz T, Wenger MK, Mendila M, Wendtner CM, Eichhorst BF, Döhner H, Hallek MJ, Kneba M.
Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall
Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8
Trial
J Clin Oncol.
2012 Mar 20;30(9):980-8
Skoetz N, Bauer K, Elter T, Monsef I, Roloff V, Hallek M, Engert A.
Alemtuzumab for patients with chronic lymphocytic leukaemia
Cochrane
Database Syst Rev. 2012 Feb 15;2:CD008078
Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Böttcher S, Staib P, Kiehl M,
Eckart MJ,
Kranz G, Goede V, Elter T, Bühler A, Winkler D, Kneba M, Döhner H, Eichhorst BF, Hallek M,
Wendtner CM
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic
leukemia:
a multicenter phase II trial of the german chronic lymphocytic leukemia study group
J Clin Oncol.
2011 Sep 10;29(26):3559-66
Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M; ESMO Guidelines Working Group
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol.
2011 Sep;22 Suppl 6:vi50-4
Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, Bergmann M, Stilgenbauer S, Hopfinger G,
Ritgen M, Bahlo J, Busch R, Hallek M
Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic
lymphocytic leukemia: results of a meta-analysis
Blood. 2011
Feb 10;117(6):1817-21
Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M, Sobh M, Choquet S, Corront B, Dearden C,
Gratwohl A, Herr W, Catovsky D, Hallek M, de Witte T, Niederwieser D, Leporrier M, Milligan D
Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of
European intergroup randomized trial comparing autografting versus observation
Blood. 2011
Feb 3;117(5):1516-21
Hallek M, Pflug N
State of the art treatment of chronic lymphocytic leukaemia
Blood Rev.
2011 Jan;25(1):1-9
Cramer P, Hallek M.
Prognostic factors in chronic lymphocytic leukemia-what do we need to know?
Nat Rev Clin
Oncol. 2011 Jan;8(1):38-47. Review
Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M,
Hopfinger G, Hensel M, Hallek M, Döhner H, Stilgenbauer S
TP53 mutation and survival in chronic lymphocytic leukemia
J Clin Oncol.
2010 Oct 10;28(29):4473-9
Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J,
Hegenbart U, Beelen D, Zeis M, Stadler M, HasenkampJ, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek
M,Kneba M, Schmitz N, Stilgenbauer S.
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic
lymphocytic leukemia: long-term clinical and MRD results of the GCLLSG CLL3X trial
Blood. 2010 Oct 7;116(14):2438-47
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen
U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B,
Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher
S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators; German
Chronic Lymphocytic Leukaemia Study Group.
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic
leukaemia: a randomised, open-label, phase 3 trial
Lancet. 2010
Oct 2;376(9747):1164-74
Schweighofer CD, Wendtner CM.
First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
Onco Targets
Ther. 2010 Jun 24;3:53-67
Hallek M.
State-of-the-art treatment of chronic lymphocytic leukemia
Hematology Am
Soc Hematol Educ Program. 2009:440-9. Review
Dreger P.
Allotransplantation for chronic lymphocytic leukemia
Hematology Am
Soc Hematol Educ Program. 2009:602-9. Review.
Böttcher S, Stilgenbauer S, Busch R, Brüggemann M, Raff T, Pott C, Fischer K, Fingerle-Rowson G, Döhner H, Hallek M, Kneba M, Ritgen M.
Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patientsafter rituximab-containing immunochemotherapy: a comparative analysis
Leukemia. 2009 Nov;23(11):2007-17
Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, Kranzhofer N, Rohrberg R, Soling U,
Burkhard O, Westermann A, Goede V, Schweighofer CD, Fischer K, Fink AM, Wendtner CM, Brittinger G, Dohner H,
Emmerich B, Hallek M; German CLL Study Group (GCLLSG)
First line therapy with fludarabine compared with chlorambucil does not result in a major benefit
for elderly patients with advanced chronic lymphocytic leukemia
Blood 2009 Oct
15;114(16):3382-91
Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, Sarno A, Groner S, Mertens D, Busch R,
Hallek M, Döhner H, Stilgenbauer S
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia
(CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a
prospective clinical trial
Blood. 2009
Sep 24;114(13):2589-97
Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U,
Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner
H; German Chronic Lymphocytic Leukemia Study Group
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results
and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study
Group
J Clin Oncol.
2009 Aug 20;27(24):3994-4001
Eichhorst B, Goede V, Hallek M.
Treatment of elderly patients with chronic lymphocytic leukemia
Leuk Lymphoma.
2009 Feb;50(2):171-8
Schweighofer CD, Ritgen M, Eichhorst BF, Busch R, Abenhardt W, Kneba M, Hallek M, Wendtner CM
Consolidation with alemtuzumab improves progression-free survival in patients with chronic
lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of
the German CLL Study Group (GCLLSG)
Br J Haematol. 2009 Jan;144(1):95-8
Ritgen M, Böttcher S, Stilgenbauer S, Bunjes D, Schubert J, Cohen S, Humpe A, Hallek M, Kneba M, Schmitz
N, Döhner H, Dreger P; German CLL Study Group
Quantitative MRD monitoring identifies distinct GVLresponse patterns after allogeneic stem cell
transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial
Leukemia. 2008
Jul;22(7):1377-86
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ,
Montserrat E, Rai KR, Kipps TJ; International Workshop on Chronic Lymphocytic Leukemia.
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:
a report from the InternationalWorkshop on Chronic Lymphocytic Leukemia
updating the National Cancer Institute–Working Group 1996 guidelines
Blood. 2008 Jun 15;111(12):5446-56
(Erratum in Blood. 2008 Dec 15;112(13):5259)
Hallek M; German CLL Study Group
Prognostic factors in chronic lymphocytic leukemia
Ann Oncol.
2008 Jun;19 Suppl 4:iv51-3
Eichhorst BF, Busch R, Stauch M, Bergmann M, Ritgen M, Kranzhöfer N, Schweighofer CD, Fischer K, Fink
A-M, Cramer P, Goede V, Wendtner CM, Hallek M, GCLLSG
No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to
Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results
of a Phase III Study of the German CLL Study Group (GCLLSG)
Blood (ASH Annual Meeting Abstracts) 2007 Nov; 110(11): Abstract
#629
Eichhorst BF, Busch R, Obwandner T, Kuhn-Hallek I, Herschbach P, Hallek M; German CLL Study Group.
Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with
fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL
Study Group
J Clin Oncol.
2007 May 1;25(13):1722-31
Eichhorst BF, Busch R, Schweighofer C, Wendtner CM, Emmerich B, Hallek M; German CLL Study Group
(GCLLSG).
Due to low infection rates no routine anti-infective prophylaxis is required in younger patients
with chronic lymphocytic leukaemia during fludarabine-based first line therapy
Br J
Haematol. 2007 Jan;136(1):63-72
Bilban M, Heintel D, Scharl T, Woelfel T, Auer MM, Porpaczy E, Kainz B, Krober A, Carey VJ, Shehata M,
Zielinski C, Pickl W, Stilgenbauer S, Gaiger A, Wagner O, Jager U; German CLL Study Group.
Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high
lipoprotein lipase expression
Leukemia. 2006 Jun;20(6):1080-8
Moosig F, Schoch R, Kneba M.
Die T-Large Granular Lymphocyte Leukämie (T-LGL-Leukämie): Eine wichtige
Differenzialdiagnose zum Felty-Syndrom
Z
Rheumatol. 2006; 65(6): 447 - 451
Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jager U, Bergmann M,
Stilgenbauer S, Schweighofer C, Wendtner CM, Dohner H, Brittinger G, Emmerich B, Hallek M; German CLL Study
Group.
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients
with chronic lymphocytic leukemia
Blood 2006; 107(3): 885 - 891
Bergmann MA, Goebeler ME, Herold M, Emmerich B, Wilhelm M, Ruelfs C, Boening L, Hallek MJ; German CLL Study
Group
Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia:
results of a phase I/II study of the German CLL Study Group
Haematologica.
2005 Oct;90(10):1357-64
Heintel D, Kienle D, Shehata M, Krober A, Kroemer E, Schwarzinger I, Mitteregger D, Le T, Gleiss A,
Mannhalter C, Chott A, Schwarzmeier J, Fonatsch C, Gaiger A, Dohner H, Stilgenbauer S, Jager U.
High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia
Leukemia
2005; 19: 1216 - 1223
Heintel D, Kroemer E, Kienle D, Schwarzinger I, Gleiss A, Schwarzmeier J, Marculescu R, Le T, Mannhalter C,
Gaiger A, Stilgenbauer S, Dohner H, Fonatsch C, Jager U; German CLL Study Group.
High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated
IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic
leukaemia
Leukemia
2004; 18(4): 756 - 62
Dreger P; German CLL Study Group; EBMT.
Transplantation strategies in chronic lymphocytic leukemia: current concepts of the German CLL Study
Group and the EBMT
Ann Hematol.
2004; 83 Suppl 1: S68 - 70
Hallek M, Eichhorst BF
Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic
leukemia
Hematol J.
2004; 5 Suppl 1: S20 - 30
Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G, Eichhorst B, Busch R, Diem H,
Engert A, Stilgenbauer S, Dohner H, Kneba M, Emmerich B, Hallek M; German CLL Study Group (GCLLSG)
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first
remission--experience on safety and efficacy within a randomized multicenter phase III trial of the
German CLL Study Group (GCLLSG)
Leukemia.
2004; 18(6): 1093 - 101
Hallek M, Bergmann M, Emmerich B
Chronic lymphocytic leukaemia: up-dated recommendations on diagnosis and treatment
Onkologie.
2004; 27(1): 97 - 104
Dreger P, Stilgenbauer S, Benner A, Ritgen M, Krober A, Kneba M, Schmitz N, Döhner H.
The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic
leukemia: a risk-matched analysis based on the VH gene mutational status
Blood 2004;
103(7): 2850 - 2858
Hallek M, Bergmann M, Goede V, Fingerle-Rowson G, Schweighofer C, Schmitt B, Wendtner CM, Emmerich B
Current concepts in chronic lymphocytic leukemia. Better chances for young patients
MMW Fortschr Med. 2003; 145(27-28): 46-9
Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, Aulitzky WE, Hensel M, Herold M, Huhn D, Hallek
M, Diehl V, Engert A; German CLL Study Group
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with
chronic lymphocytic leukemia
Blood. 2002
Nov 1;100(9):3115-20
Schmitt B, Wendtner CM, Bergmann M, Busch R, Franke A, Pasold R, Schlag R, Hopfinger G, Hiddemann W, Emmerich
B, Hallek M
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia
Clin
Lymphoma. 2002; 3(1): 26 - 35
Hallek M, Bergmann M, Emmerich B für die Deutsche CLL-Studiengruppe
Chronische lymphatische Leukämie: Aktualisierte Vorschläge zu Diagnostik und
Therapie
Dt. Ärzteblatt
2002; Jg.99 (Heft 19): A 1294 - A1301
Stilgenbauer S, Bullinger L, Lichter P and Döhner H. and the German CLL Study Group
Genetics of chronic lymphotic leukemia: genomic aberrations and VH gene mutation status in
pathogenesis andclinical course
Leukemia
2002; 16(6): 993 - 1007
Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S,
Peschel C, Emmerich B; German Chronic Lymphocytic Leukemia Study Group
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
Blood. 2001
Sep 1;98(5):1326-1331
Hallek M, Schmitt B, Wilhelm M, Busch R, Krober A, Fostitsch HP, Sezer O, Herold M, Knauf W, Wendtner CM,
Kuse R, Freund M, Franke A, Schriever F, Nerl C, Dohner H, Thiel E, Hiddemann W, Brittinger G, Emmerich B;
German Chronic Lymphocytic Leukaemia Study Group
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic
leukaemia (CLL): results of a phase II study of the German CLL Study Group
Br J
Haematol. 2001 Aug;114(2):342-348
Hallek M, Buening H, Ried M, Hacker U, Kurzeder C, Wendtner CM
Grundlagen der Gentherapie -Prinzipien und Stand der Entwicklung
Internist 2001; 42(10): 1306 - 1313
Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P
Genomic aberrations and survival in chronic lymphocytic leukemia
N Engl J Med.
2000 Dec 28;343(26):1910-6
von Bubnoff N, Adler S, Danhauser-Riedl S, Kamp T, Nerl C, Emmerich B, Hallek M
The activation of intracellular tyrosine kinases by interferon-alpha (IFNalpha) correlates with its
antiproliferative activity in B-lymphoid cell lines, but not in B-cell chronic lymphocytic leukaemia
patients
Ann Hematol
2000; 79(3): 119-126
Wendtner CM, Schmitt B, Wilhelm M, Dreger P, Montserrat E, Emmerich B, Hallek M
Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based,
risk-adapted therapy
Ann Oncol.
1999; 10(5): 505 - 509
Meinhardt G, Wendtner CM, Hallek M
Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating
cell growth and survival
J Mol Med
1999; 77(2): 282 -293
Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M
CD40-Activated B-Cell Chronic Lymphocytic Leukemia Cells for Tumor Immunotherapy: Stimulation
of Allogeneic Versus Autologous T Cells Generates Different Types of Effector Cells
Blood 1999;
93(6): 1992 - 2002
Hallek M, Langenmayer I, Nerl C, Knauf WU, Dietzfelbinger H, Adorf D, Ostwald M, Busch R, Kuhn-Hallek I Thiel
E, Emmerich B
Elevated serum thymidine kinase levels identify a subgroup at high risk of disease-progressionin
early, non-smoldering chronic lymphocytic leukemia.
Blood 1999;
93(5): 1732 - 1737
Hallek M, Kuhn-Hallek I, Emmerich B
Prognostic factors in chronic lymphocytic leukemia.
Leukemia 1997;
11 (Suppl.2): S4 - S13
Hallek M, Wanders L, Ostwald M, Busch R, Senekowitsch R, Stern S, Schick H-D, Kuhn-Hallek I, Emmerich B
Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progressionfree
survival in chronic lymphocytic leukemia and immunocytoma.
Leuk Lymphoma
1996; 22(5-6): 439 - 447
Langenmayer I, Knauf W, Nerl C, Dempster S, Hallek M, Adorf D, Dietzfelbinger H, Busch R, Ziegler-Heitbrock
HWL, Thiel E, Emmerich B
Interferon-alpha-2b (IFN alpha) for early-phase lymphocytic leukemia with high risk
disease-progression: results of a randomized multicenter study.
Br J Haematol.
1996; 94(2): 362 - 369